Spyryx starts Phase II for CF

Spyryx Biosciences Inc. (Durham, N.C.) began a Phase II trial evaluating SPX-101 in up to 78 patients with cystic fibrosis.

The placebo-controlled, Canadian and European trial will evaluate 2 dose levels of twice-daily inhaled SPX-101 for 28 days. The primary endpoint is change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline at day 28. Secondary endpoints include safety and change in clinical laboratory tests from baseline at day 28...